 |
| Research article summary (published 21 Jun 2009): |
Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Full Abstract
PURPOSE: Previously we developed membrane-arrays as a promising tool to detect circulating tumor cells (CTC) with KRAS oncogene in patients with malignancies. This study was conducted to determinate the predictive values of CTCs with KARS mutation by membrane-arrays for metastatic colorectal cancer patients treated with cetuximab plus chemotherapy. EXPERIMENTAL DESIGN: Seventy-six metastatic colorectal cancer patients receiving cetuximab plus FOLFIRI or FOLFOX-4 chemotherapy were enrolled. KRAS mutation status in the peripheral blood of these patients was analyzed using membrane-arrays, and KRAS mutation status in tumors was analyzed by DNA sequencing. RESULTS: Among 76 metastatic colorectal cancer patients, KRAS mutations in tumors and in peripheral blood were identified in 33 (43.4%) and 30 (39.5%) patients, respectively. The detection sensitivity, specificity, and accuracy of membrane-arrays for CTCs with KRAS oncogene were 84.4%, 95.3%, and 90.8%, respectively, and indeed a highly significant correlation to KRAS mutations in tumors (P < 0.0001) was observed. Forty-five (59.2%) patients responded to cetuximab plus chemotherapy, and 41 and 40 were wild-type KRAS in tumors and peripheral blood, respectively (both P < 0.0001). Patients with tumors that harbor wild-type KRAS are more likely to have a better progression-free survival and overall survival when treated with cetuximab plus chemotherapy (P < 0.0001). Likewise, patients with CTCs of wild-type KRAS in peripheral blood express a better progression-free survival and overall survival when treated with cetuximab plus chemotherapy (P < 0.0001). CONCLUSIONS: These findings provide evidence that detection of KRAS mutational status in CTCs, by gene expression array, has potential for clinical application in selecting metastatic colorectal cancer patients most likely to benefit from cetuximab therapy.
Author information
Author/s: Yen, Li-Chen (LC); Yeh, Yung-Sung (YS); Chen, Chao-Wen (CW); Wang, Hwei-Ming (HM); Tsai, Hsiang-Lin (HL); Lu, Chien-Yu (CY); Chang, Yu-Tang (YT); Chu, Koung-Shing (KS); Lin, Shiu-Ru (SR); Wang, Jaw-Yuan (JY);
Affiliation: Graduate Institute of Medicine, College of Medicine, College of Medicine, Taiwan.
Journal and publication information
Publication Type: Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res), published in United States. (Language: eng)
Reference: 2009-Jul; vol 15 (issue 13) : pp 4508-13
Dates: Created 2009/07/02; Completed 2009/10/19;
PMID: 19549774, status: MEDLINE (last retrieved date: 10/19/2009)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MeSH Headings (categories) shown below.
Note: Bold headings indicate primary MeSH headings or qualifiers.
Associated Chemicals: Antibodies, Monoclonal (0) ; Antineoplastic Agents (0) ; Folfox protocol (0) ; IFL protocol (0) ; KRAS protein, human (0) ; Organoplatinum Compounds (0) ; Proto-Oncogene Proteins (0) ; cetuximab (0) ; Fluorouracil (51-21-8) ; Leucovorin (58-05-9) ; Camptothecin (7689-03-4) ; ras Proteins (EC 3.6.5.2)Related articles
These are the most related articles currently in our database:
- [New therapeutic options in chemotherapy of advanced colorectal cancer]
13 Oct 2001 - A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma. 30 Dec 2002
- A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy.
13 Jun 1999 - Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. 28 May 2007
- Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. 2 Oct 2008
- Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. 30 Oct 2006
- Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer. 29 Nov 2007
- Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. 18 Oct 2006
- [Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma] 8 Jan 2007
- The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK). 29 Apr 1998
Related Article Map
4/29/1998
10/2/2008
Higher Relevance Score (100)
Lower Relevance Score (79)
Legend: - FREE Full text Article. - Abstract only. 
- Title only. More help.
See a larger map of 100+ related articles.